Prescription eyewear holds FDA Class I medical device classification but does not receive the same tariff exemptions granted to other low-risk medical products — a regulatory gap that became a central argument at USTR Section 301 hearings held May 5–8, 2025, at the U.S. International Trade Commission in Washington, DC.

The Vision Council testified before USTR during public hearings examining structural excess capacity across 16 economies. Omar Elkhatib, Director of Government Relations, presented five arguments for excluding eyewear and optical products from any resulting tariff actions, highlighting the inconsistent treatment of prescription eyewear under existing trade frameworks.

Classification at issue: FDA Class I designation applies to low-risk medical devices requiring the least regulatory control. Prescription eyewear meets this classification threshold, yet tariff schedules do not reflect the exemption treatment applied to comparable Class I products in other categories.

Eyewear already carries Section 301 duties from prior China tariff actions. The industry faces potential compounding effects if additional duties emerge from the current 16-economy investigation. For compliance teams managing HTS classification, this creates a multi-layered duty structure where base rates, existing Section 301 rates, and potential new rates must be tracked independently.

Optical inputs under examination include specialty polymers, acetate sheet, titanium alloys, and optical blanks. Each component category maps to distinct HTS codes with varying duty treatment. Elkhatib argued that tariffs on these imported inputs raise domestic manufacturing costs without protecting U.S. production — the inputs simply are not manufactured domestically at scale.

TradeFacts monitors this automatically. Nightly diffs on US HTS, Canada, and Mexico — delivered before your workday starts. Free 30-day trial →

The Vision Council characterized the eyewear sector as demand-driven with a high-mix supply chain — a structure that does not reflect the overcapacity dynamics the Section 301 investigation targets. More than 70% of Americans rely on prescription eyewear, making cost pass-through to patients a public health concern rather than a purely commercial consideration.

Rate caching risk: Existing Section 301 duties on optical products from China combined with potential new duties from the 16-economy investigation require compliance systems to handle additive rate structures. Static rate tables will fail to capture the layered duty treatment once USTR finalizes any actions from the May 2025 hearings.

The Vision Council requested USTR establish a review process for existing Section 301 duties related to medical devices and assess downstream affordability impacts before imposing additional duties. For engineering teams building classification logic, this signals potential future carve-outs or exclusion processes that would require HTS annotation updates.

Manufacturers relying on globally sourced optical inputs face margin compression if additional duties proceed. The tariff dashboard tools referenced by The Vision Council model financial implications but do not replace the need for accurate, current HTS rate data in production compliance systems.